Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. Sullivan Papain Block McGrath Coffinas & Cannavo, P.C.
Call Today For a Free Consultation Call For a Free Consultation (212) 732-9000
New York Personal Injury Attorneys Click for free consultation

Zantac and Generic Ranitidine Found to Contain Cancer-Causing Carcinogen NDMA

January 21, 2020 in

In September 2019, NDMA was discovered in Ranitidine, which is commonly sold under the brand name Zantac. Following this discovery by Valisure, an online specialty pharmacy, numerous manufacturers, including GlaxoSmithKline, Sandoz Inc. and Dr. Reddy’s, began recalling the over-the-counter medication internationally.

If you have been diagnosed with cancer after taking Zantac or generic ranitidine, do not hesitate to call our New York office for a free consultation with our skilled team of pharmaceutical liability attorneys. Here, the attorneys at Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. expound on the events surrounding the discovery of NDMA in ranitidine-based pharmaceuticals and your rights as a victim if you have been diagnosed with cancer after taking ranitidine.

NDMA, Classified by the EPA as a Probable Human Carcinogen, Found in Popular Antacid Zantac

Ranitidine, and its brand name Zantac, is a commonly prescribed antacid and antihistamine used to treat heartburn, stomach ulcers and other conditions related to an excess of stomach acid. N-Nitrosodimethylamine, or NDMA,  is classified as a probable human carcinogen based on results from FDA laboratory testing. The negative side effects of NDMA exposure include dizziness, headache, jaundice, nausea, and vomiting. Acute side effects include a reduction in proper organ function and even cancer. Individuals who have experienced one or more of these symptoms after taking Zantac or over-the-counter ranitidine-based drugs are advised to discuss their symptoms with a certified medical professional. They can also report these symptoms to the FDA using the agency’s MedWatch reporting system.

Valisure Found over 300,000 Times the FDA’s Daily Limit of NDMA Exposure

While the FDA’s daily limit of NDMA exposure is 96 nanograms [ng], pharmaceutical company Valisure found over 300,000 times this limit in different forms of Zantac using the FDA’s standard testing protocol. As a result, Valisure issued a Citizen’s Petition on September 9th, 2019 requesting a recall of the drug ranitidine and medications containing the drug. You can view the Citizen’s Petition here.

Global Manufacturers Have Initiated Recalls of Zantac and Ranitide-Based Drugs

After extensive testing discovered that many ranitidine-based antacids and pharmaceutical drugs contained NDMA levels astronomically higher than the safe human limit of the carcinogen, major drug manufacturers and distributors commenced global recalls of their lots of ranitidine-based drugs.

For instance, global leader in generic pharmaceuticals, Sandoz Inc., halted the distribution of generic Zantac after the alarming discovery of carcinogen-tainted ranitidine was voiced by global health regulators.

The Attorneys at Sullivan Papain Block McGrath and Cannavo P.C. Are Now Accepting Zantac Cases

The disturbing discovery of NDMA in Zantac (ranitidine) means that millions of people may have been exposed to the dangerous chemical, placing them at an increased risk for cancer.

Major pharmaceutical companies are experienced in defending legal claims, which is why you need a seasoned team of attorneys who are skilled at litigating large cases against big pharma. We will fight on your behalf and advocate for the compensation you need and deserve.

If you or a loved one were diagnosed with cancer after taking prescription Zantac or over-the-counter Zantac, contact our New York City Zantac attorneys, for a no cost consultation.